measles, mumps and rubella vaccine (live)

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for M-M-RVaxPro. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use M-M-RVaxPro.

For practical information about using M-M-RVaxPro, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 14/07/2022

Authorisation details

Product details
Agency product number
Active substance
  • measles virus Enders’ Edmonston strain (live, attenuated)
  • mumps virus Jeryl Lynn (level B) strain (live, attenuated)
  • rubella virus Wistar RA 27/3 strain (live, attenuated)
International non-proprietary name (INN) or common name
measles, mumps and rubella vaccine (live)
Therapeutic area (MeSH)
  • Rubella
  • Mumps
  • Immunization
  • Measles
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Merck Sharp & Dohme B.V. 
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Waarderweg 39
2031 BN Haarlem
The Netherlands

Product information

08/07/2022 M-M-RVaxPro - EMEA/H/C/000604 - IA/0118/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

M-M-RVaxPro is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older.

For use in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
2 ratings
7 ratings